

Determinazione del Responsabile Ufficio Formazione n° 848 del 28 APR. 2017

Oggetto: Aggiornamento Facoltativo, Dirigente Medico Dott. Maurizio Porcu

Publicata all'Albo Pretorio dell'Azienda Ospedaliera a partire dal 28 APR. 2017 per 15 giorni consecutivi e posta a disposizione per la consultazione.

Il Responsabile dell'Ufficio Formazione

- Visto** il D. Lgs. n. 502/92 e successive modificazioni ed integrazioni;
- Viste** le Leggi Regionali n. 10/2006 e n. 05/2007;
- Vista** la Deliberazione n. 263 del 04/03/2015, con la quale il Commissario Straordinario ha autorizzato il Responsabile dell'Ufficio Formazione Dott. Andrea Corrias, a predisporre le Determinazioni;
- Vista** la comunicazione Prot. n° 44 del 12.04.2017, con la quale il Direttore del Presidio San Michele ha fatto richiesta di comando facoltativo per aggiornamento, in favore del Dott. Maurizio Porcu;
- Ritenuto** di dover autorizzare la partecipazione del Dott. Maurizio Porcu al Congresso: "Heart Failure 2017" che si terrà a Parigi dal giorno 29.04.2017 al giorno 02.05.2017, per un importo presunto di € 1391,00 (milletrecentonovantuno euro) come da documentazione allegata per farne parte integrale e sostanziale;
- Considerato** che tale spesa ricadrà sul Fondo per l'aggiornamento facoltativo – Dirigenti Medici - Dipartimento di Patologia Cardiaca - anno 2017, di cui risulta verificata la copertura finanziaria e che la liquidazione dei costi sostenuti dovrà essere effettuata previa trasmissione a cura del Dott. Maurizio Porcu ai competenti Uffici della documentazione giustificativa, di una relazione sull'aggiornamento e dell'attestato di partecipazione al Congresso;

%



Segue determinazione n. 848 del 28 APR. 2017


D E T E R M I N A

Per i motivi esposti in premessa:

1. Autorizzare la partecipazione del Dott. Maurizio Porcu al Congresso: "Heart Failure 2017" che si terrà a Parigi dal giorno 29.04.2017 al giorno 02.05.2017.
2. Dare atto che l'importo complessivo presunto di € 1391,00 (milletrecentonovantauno euro) che per l'applicazione del regolamento vigente pari a € 1216,00 (milleduecentosedici euro) è a carico dell'azienda, mentre € 175,00(centosettantacinque euro) è a carico del dipendente, ricadrà sul Fondo per l'aggiornamento facoltativo – Dirigente Medici – Dipartimento Patologia Cardiaca – anno 2017, di cui risulta verificata la copertura finanziaria.
3. Disporre che la liquidazione dei costi sostenuti dal Dott. Maurizio Porcu venga effettuata previa trasmissione ai competenti Uffici della documentazione giustificativa, di una relazione sull'aggiornamento e dell'attestato di partecipazione al Congresso.
4. Trasmettere la presente determinazione al Direttore della S.C. del Personale per i conseguenti adempimenti.

Il Responsabile dell'Ufficio Formazione

Dott. Andrea Corrias



Prot.n. 44/17 del 12/09/2017

DIR. SAN. PRESIDIO

14 APR. 2017

PERVENUTO

Al Sig. Direttore Generale
Al Responsabile Ufficio Formazione
Azienda Ospedaliera Brotzu
-SEDE-

Oggetto: Richiesta aggiornamento Facoltativo

La/il sottoscritta/o DOTT. MAURIZIO PORCU
dipendente di codesta Azienda con la qualifica di DIRETTORE
in servizio presso: Struttura S.C. CARDIOLOGIA
affidente al Dipartimento di CTV

chiede di partecipare

a titolo di aggiornamento **Facoltativo** e in considerazione dell'importanza degli argomenti trattati, al seguente evento:

- Corso teorico
- Corso teorico/pratico
- Congresso
- Convegno
- Seminario
- Frequenza in altre Strutture
- Altro

Titolo dell'evento HEART FAILURE 2017

Che si terrà a PARIGI dal giorno 29/04/2017 al giorno 02/05/2017

La spesa prevista:

- Iscrizione € 660,00
- Viaggio € 250
- Vitto € 180
- Pernottamento € 300

Membro emolitivo

Spesa totale complessiva € 1381,00

Motivazione scientifica e professionale della richiesta:

RELEVANTE CONGRESSO INTERNAZIONALE SULLO SCORPENSIO CARDIACO
AREA DI INTERESSE PRIORITARIO DI QUESTO DIPARTIMENTO. I TEMI
DELLA S.C. DI CCA SONO DIRETTAMENTE COINVOLTI CON LA COMUNICAZIONE
ORALE E 2 POSTER

IL DIRETTORE DEL DIPARTIMENTO
Cardiologia CARDIACA
Firma del dipendente Porcu

Si allega: Programma Relazione

vedi WWW.ESCALDIO.ORG/CONGRESSES-8-EVENTS/HEART-FAILURE

Timbro e firma
Direttore di Struttura

IL DIRETTORE DEL DIPARTIMENTO
PATOLOGIA CARDIACA
Dott. Maurizio Porcu

[Handwritten signature]

Timbro e firma
Direttore di Dipartimento

AZIENDA OSPEDALIERA "G. BROTZU"
P.O. SAN MICHELE
DIREZIONE MEDICA
Direttore: Dott.ssa Marinella Spissu

Timbro e firma
Responsabile Ufficio Formazione
Resp.: Dott. Andrea Corrias

[Handwritten signature]
PAO Brotzu - Cagliari
UFFICIO FORMAZIONE

[Handwritten signature]
Dott. Andrea Corrias
PAO Brotzu - Cagliari
UFFICIO FORMAZIONE
Resp.: Dott. Andrea Corrias

SATURDAY 29 APRIL 2017

<ul style="list-style-type: none"> • Late Breaking Trials I (📺) • Organ dysfunction in acute heart failure • Differential diagnosis of dilated cardiomyopathy • Insuffisance cardiaque systolique en consultation (📺) • Rapid Fire 1 - Basic Science 	08:30 - 10:00	MONET ZOLA RENOIR MATISSE AGORA 2
<ul style="list-style-type: none"> • Guidelines in Daily Practice I: atrial fibrillation in heart failure • Getting the patient ready for discharge • Remote monitoring for heart failure • Surveillance post hospitalisation (📺) • Understanding cardiomyopathies. What are the mechanisms? • Off the record with L. Warner Stevenson (📺) • Rapid Fire 2 - Comorbidities 	11:00 - 12:00	MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
<ul style="list-style-type: none"> • Advancing acute heart failure treatment - quo vadis? - Sponsored by Novartis • Furosemide 2.0 - Subcutaneous administration of a novel formulation - Sponsored by scPharmaceuticals, Inc. • Heart failure with reduced ejection fraction and narrow QRS: how baroreflex stimulation help? - Sponsored by Charité Universitätsmedizin Berlin • Treating Functional Mitral Regurgitation (FMR) in heart failure with Transcatheter Mitral Valve Repair (TMVR): rendez-vous with the future now! - Sponsored by ABBOTT STRUCTURAL HEART • Updates on risk guided stratification for primary prevention of sudden cardiac death in heart failure - Sponsored by GE Healthcare 	12:15 - 13:15	HUGO ZOLA RENOIR MATISSE PIAF
<ul style="list-style-type: none"> • Journey of a heart failure patient: similarities and differences across the world - Sponsored by SERVIER • Novel transcatheter options for functional mitral regurgitation in heart failure - Sponsored by Charité Universitätsmedizin Berlin • New opportunities for an old problem: lowering potassium to maximize heart failure therapy - Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca • NT-proBNP: the gold standard biomarker in heart failure - Sponsored by Roche Diagnostics International Ltd. 	13:30 - 14:30	HUGO RENOIR MATISSE PIAF
<ul style="list-style-type: none"> • Guidelines in Daily Practice II: hospital discharge and outpatient management • Essentials of congestion in acute heart failure • Novel drugs in acute heart failure: hurdles, hype and hope • New solutions for old problems in heart failure (📺) • Insuffisance cardiaque systolique évolutive (📺) • Novel aspects of hereditary cardiomyopathies • Hot insights in metabolic interventions (📺) • Clinical Case Awards (📺) 	14:45 - 16:15	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
<ul style="list-style-type: none"> • Dilemmas in the dosing of HFrEF drugs • Acute right heart failure • Challenging clinical scenarios in acute heart failure (📺) • Controversies in cardiac resynchronisation therapy • Quand envisager une thérapeutique lourde? (📺) • Cancer and the heart • Attention needed for co-morbidities • The very best from clinical cases - I 	16:30 - 17:30	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
<ul style="list-style-type: none"> • Inaugural Session (📺) 	17:45 - 19:00	HUGO

SUNDAY 30 APRIL 2017

08:30 - 10:00	<ul style="list-style-type: none"> • Late Breaking Trials II 🌐 • Hot topics in diabetes and heart failure • What a busy clinician should know about heart failure with preserved ejection fraction? • Amyloidosis: don't miss it • Acute heart failure: immediate management • Novel drugs: how do they work? • Off the record with J. Cleland and M. Metra 🌐 • Nursing Investigator Award 🌐 	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
10:15 - 10:45	<ul style="list-style-type: none"> • The concept of timing in the therapeutic algorithm for chronic heart failure - Sponsored by SERVIER • Furosemide 2.0 - Subcutaneous administration of a novel formulation - Sponsored by scPharmaceuticals 	AGORA 1 AGORA 2
11:00 - 12:30	<ul style="list-style-type: none"> • Guidelines in Daily Practice III: pharmacological management based on LVEF 🌐 • Therapy of cardiogenic shock • Cardio-oncology: a partnership between heart failure specialists and oncologists • How to manage atrial fibrillation and low EF? 🌐 • Allez les Bleus! Groundbreaking French contributions to cardiology • Diabetes, obesity and the heart • Off the record with M. Crespo-Leiro 🌐 • Young Investigator Award: Clinical 🌐 	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
12:45 - 13:45	<ul style="list-style-type: none"> • A mitochondrial approach to heart failure - Sponsored by Charité Universitätsmedizin Berlin • Beat as one: a multidisciplinary approach to treating heart failure - Sponsored by St Jude Medical is now Abbott 	RENOIR PIAF
12:45 - 14:00	<ul style="list-style-type: none"> • Contemporary management of patients with heart failure with reduced Ejection Fraction (HFrEF) - Sponsored by Novartis • Management of co-morbidities in heart failure - Exploring new frontiers - Sponsored by Bayer AG • Implantable cardiac device therapy for heart failure: update 2017 - Sponsored by Medtronic • Iron deficiency in patients with heart failure: time for action - Sponsored by Vifor Pharma 	HUGO MONET ZOLA MATISSE
14:15 - 15:45	<ul style="list-style-type: none"> • How the results of recent randomized clinical trials will impact our practice • Management of comorbidities in chronic heart failure 🌐 • The year's best papers on heart failure 🌐 • New home-based strategies to improve physical exercise in heart failure patients • 50th anniversary of heart transplantation 🌐 • Young Investigator Award: Basic and Translational 🌐 	HUGO MONET ZOLA RENOIR MATISSE AGORA 2
15:55 - 16:25	<ul style="list-style-type: none"> • Optimising treatment of heart failure – Where are we today? - Sponsored by Novartis • Role of biomarkers to prevent heart failure development in diabetes patients - Sponsored by Roche Diagnostics International Ltd. 	AGORA 1 AGORA 2
16:00 - 16:30	<ul style="list-style-type: none"> • Award Ceremony 🌐 	HFA STAND
16:30 - 18:00	<ul style="list-style-type: none"> • The Grand Debate I: Nephilysin inhibitor - Vasodilators 🌐 🌐 🌐 • Heart failure patients with comorbidities • Practical recommendations for the clinician. How to treat... 🌐 • Emergencies in peripartum cardiomyopathy • Management of heart failure is an art: what to do when the guidelines provide no clear answer? • Sleep disordered breathing and heart failure - Time to rethink • Cardiorenal cross-roads 🌐 • Rapid Fire 3 - Acute heart failure - From diagnosis to prognosis 	HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2
18:15 - 19:15	<ul style="list-style-type: none"> • How innovative percutaneous Ventricular Assist Device (pVAD) systems improve outcomes in cardiogenic shock and facilitate complete revascularization in high risk Percutaneous Coronary Intervention (PCI) patients - Sponsored by Abiomed GmbH 	PIAF

MONDAY 1 MAY 2017

<ul style="list-style-type: none"> • Late Breaking Trials III 🕒 • Valvular disease in heart failure: vicious twins • Therapy of acute heart failure: how to use... • Heart failure management: when the clinician needs advice 🕒 • A practical guide: how to manage heart failure with mid-range ejection fraction (HFmrEF)? • Arrhythmias in heart failure - What are the mechanisms? • Ventricular assist systems: success and challenge • Rapid Fire 4 - Therapy and management 	<p>08:30 - 10:00</p>	<p>HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2</p>
<p>HFA General Assembly 🕒</p>	<p>10:05 - 10:55</p>	<p>MATISSE</p>
<ul style="list-style-type: none"> • Managing heart failure patients in day-to-day practice - Sponsored by SERVIER • Iron deficiency in patients with heart failure: implementing the guidelines in your clinical practice - Sponsored by Vifor Pharma 	<p>10:15 - 10:45</p>	<p>AGORA 1 AGORA 2</p>
<ul style="list-style-type: none"> • Guidelines in Daily Practice IV: comorbidities: valvular and kidney disease 🕒 • How to use biomarkers in acute heart failure • How to tackle congestion • How to diagnose and treat myocarditis? • Novel aspects in heart transplantation • What to target outside of cardiac myocytes in heart failure • Multimodality imaging in heart failure: already today, not tomorrow! 🕒 • The very best from clinical cases - 2 	<p>11:00 - 12:30</p>	<p>HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2</p>
<ul style="list-style-type: none"> • Heart failure, diabetes, and renal dysfunction: time for a more unified approach - Organised by Physicians Academy for Cardiovascular Education, supported by an unrestricted educational grant from Boehringer-Ingelheim and Lilly • Heart failure: what is the potential of SGLT2 inhibition? - Sponsored by AstraZeneca • Tricuspid regurgitation in heart failure: how to treat it? - Sponsored by Charité Universitätsmedizin Berlin • Understanding congestion: thinking beyond diuretic therapy - Sponsored by Fresenius Medical Care 	<p>12:45 - 13:45</p>	<p>MONET ZOLA RENOIR PIAF</p>
<ul style="list-style-type: none"> • The wearable cardioverter defibrillator: an essential tool in the management of patients at high risk for sudden cardiac death - Sponsored by ZOLL • Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels - Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma 	<p>12:45 - 14:00</p>	<p>HUGO MATISSE</p>
<ul style="list-style-type: none"> • HFA Championships 🕒 🕒 • How imaging can guide clinical decision making in heart failure • Cardiomyopathies: what the clinical cardiologist should know about... 🕒 • Comorbidities in heart failure: the bigger picture • Biomarkers in chronic heart failure • A fresh look on iron deficiency in heart failure • Off the record with M. Boehm 🕒 • Rapid Fire 5 - Diagnosis - Pathophysiology - Prognosis 	<p>14:15 - 15:45</p>	<p>HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 1 AGORA 2</p>
<ul style="list-style-type: none"> • Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels - Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma • Heart failure, diabetes, and renal dysfunction: time for a more unified approach - Sponsored by PACE-CME - Boehringer-Ingelheim/Lilly 	<p>15:55 - 16:25</p>	<p>AGORA 1 AGORA 2</p>
<ul style="list-style-type: none"> • The Grand Debate 2: ICD – Myocardial revascularisation 🕒 🕒 🕒 • Valvular disease is myocardial disease • Biomarkers in my daily practice • Challenging heart team decisions in patients with ventricular assist systems • How should comorbidities in heart failure be treated? • Highlights of translational medicine • Rapid Fire 6 - Advanced heart failure 	<p>16:30 - 18:00</p>	<p>HUGO MONET ZOLA RENOIR MATISSE PIAF AGORA 2</p>

TUESDAY 2 MAY 2017

08:30 - 10:00

- Guidelines in Daily Practice V: arrhythmias and devices 🕒
- The right ventricle: the bright side of the moon
- Takotsubo: an acute heart failure syndrome
- Heart and brain interactions in heart failure: mechanisms and therapies
- Rapid Fire 7 - Acute heart failure

MONET
ZOLA
RENOIR
MATISSE
AGORA 2

11:00 - 12:30

- Heart Failure 2017 Highlights 🕒

MONET

